This prospective, multicenter, observational study will assess the prevalence of chronic hepatitis D in patients with chronic hepatitis B in Romania and evaluate the efficacy of Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis D. Eligible patients treated with Pegasys according to current medical practice will be followed until 24 weeks after the end of treatment.
Study Type
OBSERVATIONAL
Enrollment
45
Unnamed facility
Bucharest, Romania
Proportion of chronic hepatitis B patients in Romania with chronic hepatitis D infection
Time frame: approximately 3.5 years
Response rate: Proportion of patients achieving ALT normalization and HDV RNA negativity 24 weeks after the end of treatment
Time frame: approximately 3.5 years
Virological characteristics (HBeAg/anti-HBe/HBV DNA/anti-HDV Ab/HDV RNA) of patients with chronic hepatitis D
Time frame: approximately 3.5 years
Proportion of chronic hepatitis D patients with liver cirrhosis
Time frame: approximately 3.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.